Caribou Biosciences Receives $25 Million Equity Investment from Pfizer
In addition, Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Caribou Biosciences announced on July 6, 2023 that Pfizer made a $25 million equity investment in the company, according to a company press release. The purchase by Pfizer closed on June 30, 2023.
“We believe Pfizer’s investment in Caribou highlights the potential of our clinical programs, and we are excited to establish this partnership with one of the world’s premier biopharmaceutical companies,” said Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, in a press release. “We are actively advancing our allogeneic CAR-T cell therapy pipeline and look forward to providing updates from all of our programs over the next six months, including six-month dose escalation data from our ANTLER Phase I clinical trial for CB-010, dose escalation updates on our CaMMouflage Phase I clinical trial for CB-011, and submission of an investigational new drug application for CB-012.”
Caribou will take the investment proceeds to advance CB-011, which is an immune cloaked allogeneic CAR-T cell therapy currently being evaluated in the CaMMouflage Phase I clinical trial in patients with relapsed or refractory multiple myeloma. In addition, Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Source: Caribou Biosciences
